Clinical trials: MAFLD
MAFLD, Cholecystitis
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC).
- Conditions
- MAFLD, Cholecystitis, Gallbladder Polyps, Cholelithiasis
- Trial name
- NCT07297225
- Testing
- Retrospective observational study without intervention measures
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhujiang Hospital
Metabolic- Associated Fatty Liver Disease (MAFLD)
MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients
Metabolic-associated fatty liver disease (MAFLD), is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty infiltration.
- Trial name
- NCT06492369
- Where
- Egypt
- Volunteers
- 382 people
- Sponsor
- Tanta University
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
Fatty Liver Disease, Fatty Liver
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
- Trial name
- MAFLD (NCT05966025)
- Testing
- Itopride, conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
Hyperuricemia and MAFLD
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD.
- Trial name
- SUMA (NCT07053709)
- Volunteers
- 200 people
- Sponsor
- Assiut University
Metabolic Dysfunction-associated Fatty Liver Disease, Metabolic Disease
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis
This study aim to find out metabolic molecules in blood and urine which could identify high risk of advanced fibrosis in MAFLD patients via NMR-based metabolic profiling.
- Trial name
- NCT05734599
- Testing
- NMR-based metabolic profiling
- Where
- China
- Volunteers
- 1,194 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Metabolic Associated Fatty Liver Disease
MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes
Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis.
- Trial name
- NCT04761900
- Testing
- the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
- Volunteers
- 3,372 people
- Sponsor
- Ningbo No. 1 Hospital
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Optimal Measurement of Spleen Stiffness Among Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
A growing number of people are being diagnosed with fatty liver disease, also known as metabolic-dysfunction associated liver disease (MASLD).
- Trial name
- NCT06953830
- Testing
- Vibration-controlled transient elastography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- William Jennings Bryan Dorn VA Medical Center
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
MAFLD, HEPATITIS B CHRONIC
Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients
This single-center cross-sectional study aims to evaluate the agreement between a handheld elastography device and the iLivTouch transient elastography system for the noninvasive assessment of liver fibrosis and steatosis in…
- Trial name
- NCT07242404
- Volunteers
- 224 people
- Sponsor
- Hong You
NASH, NAFLD
RE and Probiotics in MAFLD/NAFLD
This project aims to evaluate the roles of the autonomic nervous system (ANS) and gut microbiota as correlates of clinical improvement in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver…
- Conditions
- NASH, NAFLD, MAFLD
- Trial name
- NCT06563921
- Testing
- physical exercise programme, probiotics supplementation
- Volunteers
- 180 people
- Sponsor
- Nicolaus Copernicus University
MAFLD
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
Cirrhosis associated with metabolic associated fatty liver disease (MAFLD) can lead to a series of adverse outcomes in and outside the liver, but there is no approved treatment so far.
- Trial name
- DISMA (NCT07233486)
- Testing
- Digital Intelligence Software Intervention Group
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Clinical Classification of MAFLD Based Liver Biopsy
Metabolic dysfunction-associated Fatty Liver Disease (MAFLD), also known as Non-Alcoholic Fatty Liver Disease (NAFLD), is the most common chronic progressive liver disease in China.
- Trial name
- NCT06795646
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Fatty Liver Disease, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF
Ultrasound Derived Fat Fraction (UDFF) Evaluation of Metabolic Related Fatty Liver Disease (MAFLD) in obesity Patients Metabolic fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is the most…
- Trial name
- NCT06097338
- Testing
- bariatric surgery (BS)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Type 2 Diabetes
Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes.
- Trial name
- NCT06304844
- Testing
- transient elastography (Fibroscan)
- Volunteers
- 300 people
- Sponsor
- Sohag University